Sonoma Pharmaceuticals, Inc. (SNOA) stock
SNOANasdaqSurgical & Medical Instruments & ApparatusFiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3078% below fair value
$1.09−0.08 (-6.84%)
Close on Nov 13, 2026Market cap $5.22MP/E –Yield –
Sonoma Pharmaceuticals operating margin
Operating margin is operating income as a percentage of revenue.
Sonoma Pharmaceuticals's operating margin for the twelve months ending Sep 30, 2026 was -3.3%. For fiscal 2026 it was -12.6%, against -26.0% the year before. The highest annual figure on record is -12.6% in fiscal 2026.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | -12.6% | +13.4 |
| FY2025 | Mar 31, 2025 | -26.0% | +10.9 |
| FY2024 | Mar 31, 2024 | -36.9% | −2.5 |
| FY2023 | Mar 31, 2023 | -34.4% | +12.2 |
| FY2022 | Mar 31, 2022 | -46.6% | −28.1 |
| FY2021 | Mar 31, 2021 | -18.5% | +22.7 |
| FY2020 | Mar 31, 2020 | -41.2% | +18.1 |
| FY2019 | Mar 31, 2019 | -59.3% | +25.8 |
| FY2018 | Mar 31, 2018 | -85.2% | +16.0 |
| FY2017 | Mar 31, 2017 | -101.2% | +55.9 |
| FY2016 | Mar 31, 2016 | -157.0% | −109.0 |
| FY2015 | Mar 31, 2015 | -48.1% | −3.8 |
| FY2014 | Mar 31, 2014 | -44.3% | −22.4 |
| FY2013 | Mar 31, 2013 | -21.8% | +28.9 |
| FY2012 | Mar 31, 2012 | -50.7% | +26.2 |
| FY2011 | Mar 31, 2011 | -76.9% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2027CQ3 2026 | Sep 30, 2026 | 4.0% | +10.1 |
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | -0.6% | +26.6 |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | -6.3% | +11.2 |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | -15.6% | +13.3 |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | -6.0% | +17.7 |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | -27.3% | +7.3 |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | -17.5% | +23.5 |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | -28.9% | −2.0 |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | -23.7% | +20.5 |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | -34.6% | +1.6 |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | -41.0% | −2.9 |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | -26.9% | +35.4 |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | -44.2% | −22.3 |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | -36.2% | −14.7 |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | -38.1% | +95.1 |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | -62.3% | −29.3 |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | -21.9% | +3.8 |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | -21.5% | +3.1 |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | -133.2% | −2.7 |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | -33.0% | −30.2 |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | -25.7% | −28.7 |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | -24.5% | −13.0 |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | -130.5% | −55.7 |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | -2.8% | +22.4 |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | 2.9% | +30.2 |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | -11.5% | +27.9 |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | -74.8% | −13.1 |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | -25.2% | +19.3 |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | -27.2% | +26.5 |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | -39.4% | +41.9 |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | -61.7% | +68.2 |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | -44.5% | +21.6 |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | -53.7% | +12.4 |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | -81.3% | +6.9 |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | -129.9% | −57.7 |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | -66.1% | +40.0 |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | -66.1% | – |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | -88.2% | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | -72.3% | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | -106.1% | – |
See a number that looks wrong?